Reduced-dose Versus Standard Dose Radiotherapy for Nasopharyngeal Carcinomain

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
To study the 2-year PFS (progression-free survival) of patients with stage II-III nasopharyngeal carcinoma treated with induction chemotherapy followed by two different doses of intensity modulated radiation therapy plus concurrent cisplatin chemotherapy
Epistemonikos ID: 1df0f8b67f16db494afb73aeb7cedd77a12c11fe
First added on: May 13, 2024